Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
cytarabine
i
Other names:
HiDAC, LDAC
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(99)
News
Trials
Company:
Generic mfg.
Drug class:
DNA synthesis inhibitor, DNA-directed DNAP inhibitor
Related drugs:
‹
cisplatin (330)
gemcitabine (181)
temozolomide (114)
oxaliplatin (57)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
nedaplatin (6)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine-releasing intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
DFP-10917 (0)
CYC682 (0)
cisplatin (330)
gemcitabine (181)
temozolomide (114)
oxaliplatin (57)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
mitomycin (10)
temozolomide gel (7)
nedaplatin (6)
fludarabine IV (6)
nelarabine (5)
bleomycin (4)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
FF-10502 (2)
fotemustine (2)
streptozocin (2)
fludarabine oral (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
gemcitabine-releasing intravesical system (1)
mitomycin urothelial gel (1)
melphalan hepatic delivery system (1)
INT230-6 (1)
Ganfule (0)
liposomal cisplatin (0)
MKC-1106 (0)
miriplatin (0)
zinostatin (0)
pegylated liposomal mitomycin-c prodrug (0)
mercaptopurine oral suspension (0)
gemcitabine with RenovoCath (0)
cytarabine ocfosfate (0)
TG6002 (0)
dimesna (0)
mitomycin intravesicular (0)
SY-2101 (0)
captisol-enabled melphalan (0)
CO 1.01 (0)
D07001 (0)
TAS-118 (0)
PRV211 (0)
LP-100 (0)
PCS3117 (0)
PTX-200 (0)
DFP-10917 (0)
CYC682 (0)
›
Associations
(99)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Burkitt Lymphoma
No biomarker
Burkitt Lymphoma
cytarabine + methotrexate
Sensitive: A2 - Guideline
cytarabine + methotrexate
Sensitive
:
A2
cytarabine + methotrexate
Sensitive: A2 - Guideline
cytarabine + methotrexate
Sensitive
:
A2
No biomarker
Lymphoma
No biomarker
Lymphoma
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
cytarabine + methotrexate + idarubicin
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin
Sensitive
:
A2
cytarabine + methotrexate + idarubicin
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin
Sensitive
:
A2
No biomarker
Childhood B Acute Lymphoblastic Leukemia
No biomarker
Childhood B Acute Lymphoblastic Leukemia
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive: A2 - Guideline
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive
:
A2
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive: A2 - Guideline
cytarabine + cyclophosphamide + methotrexate + vincristine + pegaspargase
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
cytarabine
Sensitive: A2 - Guideline
cytarabine
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + fludarabine IV + GCSF
Sensitive
:
A2
cytarabine + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + fludarabine IV + GCSF
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive
:
A2
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + fludarabine IV + GCSF
Sensitive
:
A2
No biomarker
Acute Promyelocytic Leukemia
No biomarker
Acute Promyelocytic Leukemia
cytarabine + daunorubicin
Sensitive: A2 - Guideline
cytarabine + daunorubicin
Sensitive
:
A2
cytarabine + daunorubicin
Sensitive: A2 - Guideline
cytarabine + daunorubicin
Sensitive
:
A2
FLT3-TKD mutation
Acute Myelogenous Leukemia
FLT3-TKD mutation
Acute Myelogenous Leukemia
cytarabine + midostaurin + daunorubicin
Sensitive: A2 - Guideline
cytarabine + midostaurin + daunorubicin
Sensitive
:
A2
cytarabine + midostaurin + daunorubicin
Sensitive: A2 - Guideline
cytarabine + midostaurin + daunorubicin
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + daunorubicin
Sensitive: A2 - Guideline
cytarabine + daunorubicin
Sensitive
:
A2
cytarabine + daunorubicin
Sensitive: A2 - Guideline
cytarabine + daunorubicin
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + idarubicin hydrochloride
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride
Sensitive
:
A2
cytarabine + idarubicin hydrochloride
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + etoposide IV + mitoxantrone
Sensitive: A2 - Guideline
cytarabine + etoposide IV + mitoxantrone
Sensitive
:
A2
cytarabine + etoposide IV + mitoxantrone
Sensitive: A2 - Guideline
cytarabine + etoposide IV + mitoxantrone
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + etoposide IV
Sensitive: A2 - Guideline
cytarabine + etoposide IV
Sensitive
:
A2
cytarabine + etoposide IV
Sensitive: A2 - Guideline
cytarabine + etoposide IV
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + cladribine + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
cytarabine + cladribine + Nugraf (filgrastim biosimilar)
Sensitive
:
A2
cytarabine + cladribine + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
cytarabine + cladribine + Nugraf (filgrastim biosimilar)
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + clofarabine
Sensitive: A2 - Guideline
cytarabine + clofarabine
Sensitive
:
A2
cytarabine + clofarabine
Sensitive: A2 - Guideline
cytarabine + clofarabine
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar)
Sensitive
:
A2
cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
cytarabine + idarubicin hydrochloride + cladribine + Nugraf (filgrastim biosimilar)
Sensitive
:
A2
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar)
Sensitive
:
A2
cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar)
Sensitive: A2 - Guideline
cytarabine + mitoxantrone + cladribine + Nugraf (filgrastim biosimilar)
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
cytarabine + methotrexate + idarubicin hydrochloride
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin hydrochloride
Sensitive
:
A2
cytarabine + methotrexate + idarubicin hydrochloride
Sensitive: A2 - Guideline
cytarabine + methotrexate + idarubicin hydrochloride
Sensitive
:
A2
No biomarker
Lymphoma
No biomarker
Lymphoma
cytarabine + thiotepa
Sensitive: A2 - Guideline
cytarabine + thiotepa
Sensitive
:
A2
cytarabine + thiotepa
Sensitive: A2 - Guideline
cytarabine + thiotepa
Sensitive
:
A2
No biomarker
B Acute Lymphoblastic Leukemia
No biomarker
B Acute Lymphoblastic Leukemia
cytarabine + etoposide IV + mitoxantrone
Sensitive: A2 - Guideline
cytarabine + etoposide IV + mitoxantrone
Sensitive
:
A2
cytarabine + etoposide IV + mitoxantrone
Sensitive: A2 - Guideline
cytarabine + etoposide IV + mitoxantrone
Sensitive
:
A2
No biomarker
Lymphoma
No biomarker
Lymphoma
cytarabine + methotrexate + thiotepa
Sensitive: A2 - Guideline
cytarabine + methotrexate + thiotepa
Sensitive
:
A2
cytarabine + methotrexate + thiotepa
Sensitive: A2 - Guideline
cytarabine + methotrexate + thiotepa
Sensitive
:
A2
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
No biomarker
T Cell Non-Hodgkin Lymphoma
No biomarker
T Cell Non-Hodgkin Lymphoma
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
No biomarker
Peripheral T-cell Lymphoma
No biomarker
Peripheral T-cell Lymphoma
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
carboplatin + cytarabine + dexamethasone
Sensitive: A2 - Guideline
carboplatin + cytarabine + dexamethasone
Sensitive
:
A2
FLT3-ITD mutation
Acute Myelogenous Leukemia
FLT3-ITD mutation
Acute Myelogenous Leukemia
cytarabine
Resistant: B - Late Trials
cytarabine
Resistant
:
B
cytarabine
Resistant: B - Late Trials
cytarabine
Resistant
:
B
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
cytarabine
Sensitive: B - Late Trials
cytarabine
Sensitive
:
B
cytarabine
Sensitive: B - Late Trials
cytarabine
Sensitive
:
B
IDH2 mutation
Acute Myelogenous Leukemia
IDH2 mutation
Acute Myelogenous Leukemia
cytarabine
Resistant: B - Late Trials
cytarabine
Resistant
:
B
cytarabine
Resistant: B - Late Trials
cytarabine
Resistant
:
B
NPM1 mutation
Acute Myelogenous Leukemia
NPM1 mutation
Acute Myelogenous Leukemia
cytarabine + idarubicin hydrochloride
Sensitive: C2 – Inclusion Criteria
cytarabine + idarubicin hydrochloride
Sensitive
:
C2
cytarabine + idarubicin hydrochloride
Sensitive: C2 – Inclusion Criteria
cytarabine + idarubicin hydrochloride
Sensitive
:
C2
FLT3 mutation
Acute Myelogenous Leukemia
FLT3 mutation
Acute Myelogenous Leukemia
cytarabine + midostaurin
Sensitive: C2 – Inclusion Criteria
cytarabine + midostaurin
Sensitive
:
C2
cytarabine + midostaurin
Sensitive: C2 – Inclusion Criteria
cytarabine + midostaurin
Sensitive
:
C2
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
MYC rearrangement + BCL2 rearrangement
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
BCL2 expression + MYC expression
Diffuse Large B Cell Lymphoma
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
cytarabine + methotrexate
Resistant: C3 – Early Trials
cytarabine + methotrexate
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login